New sedative studied in patients with low protein levels
NCT ID NCT06425757
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at how the sedative drug ciprofol is processed in the body of people with moderate to severe low blood protein (hypoproteinemia). Researchers measured drug levels in the blood after a single injection in 36 patients. The goal was to understand dosing and timing, not to treat the condition itself.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CIPROFOL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Zhejiang Cancer Hospital
Hangzhou, Zhejang, 310000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a natural antibody quiet inflammation? a new trial investigates
- Can a simple calcium tablet help prevent postpartum bleeding?
- First human trial launches for Hemay5259: a new Extended-Release drug candidate
- Safer anesthesia for kids? study hunts for ideal ciprofol dose
- Morning or afternoon surgery? study tests if body clock alters anesthesia safety
- Apples' hidden power: study probes how polyphenols scavenge harmful carbonyls